Discover
XRTX
XORTX Therapeutics Inc.
0.38
33 x 2.01
2 x 2.07
bid
ask
+
0.03
9.88%
04:00 PM
| Ytd | -86.51% | |
| 1y | -92.18% |
0.35
day range
0.40
1.73
52 week range
7.05
| Open | 0.39 | Prev Close | 0.34 | Low | 0.35 | High | 0.40 | Mkt Cap | 568.12K |
| Vol | 0.00 | Avg Vol | 45.48K | EPS | -1.35 | P/E | -1.51 | Forward P/E | -0.67 |
| Beta | 0.74 | Short Ratio | 0.02 | Inst. Own | 6.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.21 | 200-d Avg | 2.64 | 1yr Est | 12.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.2 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | 0.06 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -1.24 | N/A | N/A |
| 2024-04-02 | 2023-12 | 0 | -0.48 | N/A | N/A |
| 2023-11-14 | 2023-09 | 0 | -6.03 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -0.81 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-11-10 | Davidoff, Allen Warren | Director of Issuer | 440.92K | Acquisition or disposition in the public market |
| 2021-12-01 | Keshri (Amar Deep) | Senior Officer of Issuer | 8.50K | Acquisition or disposition in the public market |
| 2022-01-19 | MacDonald (David) | Senior Officer of Issuer | 20.00K | Opening Balance-Initial SEDI Report |
| 2022-01-11 | Pratt (Raymond Dennis M.D.) | Director of Issuer | 0.00 | Opening Balance-Initial SEDI Report |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | UBS Group AG | 18.78K | 21.03K | 0.54% |
| 2024-09-29 | National Bank of Canada/FI | 3.44K | 3.85K | 0.10% |
| 2024-09-29 | Osaic Holdings Inc | 1.15K | 1.29K | 0.03% |
| 2024-09-29 | Royal Bank of Canada | 672.00 | 752.00 | 0.02% |
| 2024-09-29 | JP Morgan Chase & Company | 254.00 | 284.00 | 0.01% |
| 2024-09-29 | Clearstead Advisors, LLC | 277.00 | 310.00 | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|
Dividend
| Dividend | Date |
|---|---|
| 0.0001 | 2014-01-31 |
| 0.0001 | 2013-10-15 |
| 0.0001 | 2013-07-11 |
| 0.0001 | 2013-04-16 |
| 0.0001 | 2012-12-24 |
| 0.0001 | 2012-10-12 |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2026-04-06 |
| 1 : 9 | 2023-11-14 |
| 1 : 9 | 2023-11-10 |
| 1 : 12 | 2021-09-23 |